Temozolomide in malignant gliomas: Current use and future targets

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 647-655

  Villano, J Lee ^a   Seery, Tara E ^a   Bressler, Linda R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alkylating chemotherapy; Brain tumor; Glioblastoma; Malignant glioma; Temozolomide; Tumor resistance

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 6 O BENZYLGUANINE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARMUSTINE; CEP 8983; CORTICOSTEROID; COTRIMOXAZOLE; DNA; ENZYME INHIBITOR; LOMEGUATRIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; APLASTIC ANEMIA; ASTROCYTOMA; BEDTIME DOSAGE; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DNA REPAIR; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EXCISION REPAIR; FATIGUE; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMAN; INFECTION PREVENTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MELANOMA; METHYLATION; MISMATCH REPAIR; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PNEUMOCYSTIS PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; RADIATION NECROSIS; SHORT SURVEY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS;

EID: 68149157509     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1050-5     Document Type: Short Survey

References (62)

1. R Stupp WP Mason MJ van den Bent 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996
2. R Stupp ME Hegi WP Mason 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466
3. CBTRUS (2008) Statistical report: primary brain tumors in the United States, 2000-2004. In: Edition Published by the Central Brain Tumor Registry of the United States 2008
4. LA Stewart 2002 Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 1011 1018
5. HA Fine KB Dear JS Loeffler 1993 Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 2585 2597
6. M Westphal DC Hilt E Bortey 2003 A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro Oncol 5 79 88
7. http://www.accessdata.fda.gov/scripts/cder/onctools/druglist.cfm. Accessed 19 May 2009
8. R Stupp PY Dietrich S Ostermann Kraljevic 2002 Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 1375 1382
9. WK Yung RE Albright J Olson 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588 593
10. WK Yung MD Prados R Yaya-Tur 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 2762 2771
11. WJ Curran Jr CB Scott J Horton 1993 Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 704 710
12. RO Mirimanoff T Gorlia W Mason 2006 Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2563 2569
13. M Esteller J Garcia-Foncillas E Andion 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354
14. ME Hegi AC Diserens T Gorlia 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003
15. F Keime-Guibert O Chinot L Taillandier 2007 Radiotherapy for glioblastoma in the elderly N Engl J Med 356 1527 1535
16. OL Chinot M Barrie E Frauger 2004 Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations Cancer 100 2208 2214
17. M Glantz M Chamberlain Q Liu 2003 Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas Cancer 97 2262 2266
18. Kimple RJ, Grabowski S, Papez M et al (2008) Glioblastoma in the elderly: radiation, chemoradiation, and supportive care. J Clin Oncol 26 (abstr 20738)
19. 14C-temozolomide following oral administration to patients with advanced cancer Clin Cancer Res 5 309 317
20. ES Newlands MF Stevens SR Wedge 1997 Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35 61
21. LL Muldoon C Soussain K Jahnke 2007 Chemotherapy delivery issues in central nervous system malignancy: a reality check J Clin Oncol 25 2295 2305
22. F Marchesi M Turriziani G Tortorelli 2007 Triazene compounds: mechanism of action and related DNA repair systems Pharmacol Res 56 275 287
23. T Kanzawa J Bedwell Y Kondo 2003 Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide J Neurosurg 99 1047 1052
24. 6-methylguanine Oncogene 26 186 197
25. DS Ziegler AL Kung MW Kieran 2008 Anti-apoptosis mechanisms in malignant gliomas J Clin Oncol 26 493 500
26. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 1004 1011
27. C Balmaceda D Peereboom S Pannullo 2008 Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas Cancer 112 1139 1146
28. W Wick M Platten M Weller 2009 New (alternative) temozolomide regimens for the treatment of glioma Neuro Oncol 11 69 79
29. G Gasparini 2001 Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2 733 740
30. JT Kim JS Kim KW Ko 2006 Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas Oncol Rep 16 33 39
31. H Kurzen S Schmitt H Naher T Mohler 2003 Inhibition of angiogenesis by non-toxic doses of temozolomide Anticancer Drugs 14 515 522
32. SM Lee M Brada S Stenning L Thompson R Gabe 2008 A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12 ISRCTN83176944) Ann Oncol 19 viii2 (LBA 5)
33. 6- alkylguanine DNA alkyltransferase as a means to enhance chemotherapy Cancer Treat Rev 32 261 276
34. 6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro Pharmacol Res 53 317 323
35. 6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report Clin Cancer Res 13 6712 6718
36. 6-benzylguanine for patients with recurrent or progressive malignant glioma J Clin Oncol 23 7178 7187
37. 6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors Clin Cancer Res 12 1577 1584
38. OA Khan M Ranson M Michael 2008 A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer Br J Cancer 98 1614 1618
39. M Ranson P Hersey D Thompson 2007 Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma J Clin Oncol 25 2540 2545
40. S Miknyoczki H Chang J Grobelny 2007 The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity Mol Cancer Ther 6 2290 2302
41. CK Donawho Y Luo Y Luo 2007 ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 2728 2737
42. V Ganiere G Christen F Bally 2006 Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide Nat Clin Pract Oncol 3 339 343 (quiz following 343)
43. FDA 2007 Temozolomide (marketed as Temodar): aplastic anemia Drug Saf Newsl 1 7
44. Doyle TJ, Mikkelsen T, Croteau D et al (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): report of a Phase II trial. J Clin Oncol 23 (abstract #1546)
45. R Jalali P Singh H Menon S Gujral 2007 Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide J Neurooncol 85 105 107
46. B Morris U Reiss K Kasow A Broniscer 2008 Bone marrow transplantation (BMT) for aplastic anemia secondary to temozolomide therapy in a long-term survivor with glioblastomamultiforme (GBM) Neuro Oncol 10 396 (abstract CR2)
47. N Singhal S Selva-Nayagam MP Brown 2007 Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment-case study and review of literature J Neurooncol 85 229 230
48. JL Villano CA Collins EE Manasanch 2006 Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide Lancet Oncol 7 436 438
49. DE Gerber SA Grossman M Zeltzman 2007 The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas Neuro Oncol 9 47 52
50. V Noronha N Berliner KK Ballen 2006 Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature Neuro Oncol 8 280 283
51. YW Su MC Chang MF Chiang RK Hsieh 2005 Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma J Neurooncol 71 315 318
52. MC Chamberlain MJ Glantz L Chalmers 2007 Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 81 83
53. W Taal D Brandsma HG de Bruin 2008 Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide Cancer 113 405 410
54. AA Brandes E Franceschi A Tosoni 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197
55. JD Ruben M Dally M Bailey 2006 Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy Int J Radiat Oncol Biol Phys 65 499 508
56. P Giglio MR Gilbert 2003 Cerebral radiation necrosis Neurologist 9 180 188
57. Gerstner ER, McNamara MB, Norden AD et al (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol [Epub ahead of print]
58. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280
59. D Quan DB Hackney AA Pruitt 1999 Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS Neurology 53 211 213
60. S Ananthnarayan J Bahng J Roring 2008 Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol 88 339 347
61. P Hau D Koch T Hundsberger 2007 Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma Neurology 68 688 690
62. R Stupp AF Hottinger 2008 Management of malignant glioma-quo vadis? Onkologie 31 300 302